Lung Sarcomatoid Carcinoma
Hutchison Medipharma Limited
This is a Phase II, open-label, multicenter study of Savolitinib administered orally once per day(QD) to locally advanced/metastatic PSC patients with MET Exon 14 mutation. The targeted population is the patients with MET Exon 14 mutation who have failed prior systemic therapy (ies), or are unwilling or unable to receive chemotherapy. Pathological diagnosis will be confirmed retrospectively by the central pathological laboratory.
- Drug: SavolitinibEnrolled patients will be treated with Savolitinib 600mg once per day(QD), till disease progression, death or unacceptable toxicity, whichever comes first. A cycle of study treatment will be defined as 21 days of continuous dosing.
|Ages eligible for Study||18 Years and older|
|Genders eligible for Study||All|
|Accepts Healthy Volunteers||No|
- 1.Fully understood the study and voluntarily signed Informed Consent Form
- 2.Age > 18 years
- 3.Histologically or cytologically documented locally advanced or Metastatic pulmonary sarcomatoid carcinoma (PSC) patients with MET Exon 14 mutation who have failed piror systemic therapy(ies), or are unwilling or unable to receive chemotherapy
- 4.Patient should have measurable disease per RECIST1.1
- 5.ECOG performance status of 0, or 1
- 6.Expected survival > 12 weeks
- 1.Co-existing malignancy or malignancies diagnosed within the last 3 years other than lung cancer with the exception of adequately treated skin basal cell carcinoma or cervical cancer in situ.
- 2.Any anti-cancer therapy, including chemotherapy, hormonal therapy, biologic therapy or radiotherapy within 3weeks prior to initiation of study treatment, or received TKI (for ex. EGFR-TKI) treatment within 2 week prior to initiation of study treatment
- 3.Palliative radiation to bone metastases within 2 weeks prior to the initiation of study treatment
- 4.Herbal therapy within 1 week prior to the initiation of study treatment
Savolitinib will be administrated 600mg once per day (QD). The treatment will be discontinued for the patients who experience disease progression, death or experience unacceptable toxicity, whichever occurs first. A cycle of study treatment will be defined as 21 days of continuous dosing.
- Shanghai Chest HospitalrecruitingShanghai, Shanghai, China, 210000
30 November, 2016
13 July, 2017